Buy GARDASIL® 9 (Slovakian) Online

$219.00

Group Buy $208
Brand

GARDASIL®

Manufacturer

MSD

Active Substances

Strength

0.5ml

Pack Size

1 x 0.5ml Vial, 1 x Pre-Filled Syringe

Free Shipping Over $500

With fast order dispatch

Guaranteed Product Authenticity

All products contain original LOT numbers

Secure SSL
Encryption

Your data is safe with us

Group Buy
Program

Join group orders for exclusive volume discounts.

GARDASIL 9 is a vaccine indicated for the prevention of various diseases caused by specific types of Human Papillomavirus (HPV). The primary target group includes both girls and boys aged 9 through 45 years. It is designed to prevent:

  • Cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
  • Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
  • Precancerous lesions:
    • Cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3.
    • Vulvar intraepithelial neoplasia (VIN) grades 2 and 3.
    • Vaginal intraepithelial neoplasia (VaIN) grades 2 and 3.
    • Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.

Important Notes:

  • The vaccine is not a treatment for existing HPV infections or lesions.
  • Continued screening for cancers is required even after vaccination.

GARDASIL 9 Dosage Information

The standard dosage for GARDASIL 9 is 0.5 mL per dose, administered via intramuscular injection. The vaccine schedule depends on the patient’s age:

  • 9 through 14 years:
    • 2-dose schedule at 0 months and 6-12 months.
    • 3-dose schedule at 0, 2, and 6 months (if required).
  • 15 through 45 years:
    • 3-dose schedule at 0, 2, and 6 months.

GARDASIL 9 Key Points:

  • If the second dose in the 2-dose regimen is administered earlier than 5 months after the first dose, a third dose is required.
  • The vaccine should be administered in the deltoid or anterolateral thigh region.
  • Patients should be observed for 15 minutes after administration due to the potential for syncope.

GARDASIL 9 Side Effects and Precautions

The most commonly reported side effects are localized to the injection site and include:

  • Injection-site pain:
    • 89.9% in women aged 16-26 years.
    • 71.5% in boys aged 9-15 years.
  • Injection-site swelling:
    • 40.0% in women aged 16-26 years.
    • 47.8% in boys aged 9-15 years.
  • Headache:
    • 14.6% in women aged 16-26 years.
    • 11.4% in boys aged 9-15 years.

GARDASIL 9 Serious Adverse Reactions:

  • Syncope: Occasional fainting episodes, sometimes associated with seizure-like activity. Observation is recommended for 15 minutes post-injection.
  • Allergic Reactions: Patients with hypersensitivity to yeast or previous doses of GARDASIL® or GARDASIL 9 should not receive the vaccine.

GARDASIL 9 Postmarketing Experience:

  • Rare reports of autoimmune hemolytic anemia, Guillain-Barré syndrome, and acute disseminated encephalomyelitis were noted.

GARDASIL 9 Clinical Studies and Real-World Outcomes

In clinical trials, GARDASIL 9 has shown high efficacy in preventing HPV-related diseases. Here are some of the key findings from the clinical studies:

  • Girls and Women (16-26 years):
    • 98.2% efficacy in preventing HPV 16- and 18-related CIN 2/3 and adenocarcinoma in situ (AIS).
    • 100% efficacy in preventing HPV 16- or 18-related VIN 2/3 and VaIN 2/3.
  • Boys and Men (16-26 years):
    • 90.6% efficacy in preventing HPV 6, 11, 16, and 18-related external genital lesions.
  • Extended Efficacy: Follow-up studies indicated 100% efficacy against cervical and genital disease for up to 60 months post-vaccination.

GARDASIL 9 Drug Interactions

While no extensive studies on GARDASIL 9 interactions with other medications have been conducted, caution is advised when co-administering with immunosuppressive therapies, as these can reduce the vaccine’s efficacy.

GARDASIL 9 Use in Specific Populations

  • Pregnancy: Data from clinical studies do not suggest an increased risk of birth defects when GARDASIL 9 is administered during pregnancy, but pregnant women should typically defer vaccination.
  • Lactation: There is insufficient data to assess the impact of the vaccine on breastfeeding infants, though the benefits of breastfeeding should be weighed against the mother’s need for the vaccine.
  • Pediatric Use: Safety and effectiveness are established in individuals 9 years and older. Efficacy in children younger than 9 years is not established.